EML4‐ALK lung cancer patients do not necessarily express only one secondary mutation but can express double and even triple mutations such as S1206F/G1202R/G1269A simultaneously as a scheme of increasing on‐target resistance [32]. The gene discussed is ALK; the disease is lung cancer.